Emergency Department, Linyi People's Hospital, Linyi, 276003, Shandong, China.
Department of Endocrinology and Metabolism, Linyi People's Hospital, Linyi, 276000, Shandong, China.
Mol Neurobiol. 2016 Nov;53(9):6407-6412. doi: 10.1007/s12035-015-9523-5. Epub 2015 Nov 19.
The prognostic factors associated with the survival of glioma patients have not been well established. Loss of heterozygosity (LOH) of 9p was known to be a typical molecular signature of gliomas, but it was still unclear whether LOH of 9p was associated with poorer survival in patients with gliomas. We searched PubMed and Embase databases from the earliest records to May 2015 to identify studies that met the inclusion criteria. Either a fixed- or a random-effects model was used to calculate the pooled hazard ratio (HR) according to the between-study heterogeneity. Thirteen eligible studies involving 1465 cases of gliomas were included in the meta-analysis. There was little between-study heterogeneity (I = 15 %), and the fixed-effects model was used to calculate the pooled HR. Meta-analysis of total 13 studies showed that LOH of 9p was significantly associated with poorer prognosis of glioma patients (HR = 1.39, 95%CI 1.17-1.64, P = 0.0002). Meta-analysis of eight studies reporting adjusted estimates showed that LOH of 9p was independently associated with poorer prognosis of glioma patients (HR = 1.40, 95%CI 1.14-1.72, P = 0.001). Subgroup analysis by types of gliomas showed that LOH of 9p was significantly associated with poorer prognosis in patients with glioblastoma (HR = 1.34, 95%CI 1.01-1.78, P = 0.04). There was no obvious risk of publication bias shown in the funnel plot. LOH of 9p is significantly associated with poorer prognosis of glioma patients, which is a useful biomarker in predicting patients' survival.
9p 杂合性缺失与胶质瘤患者生存相关的预后因素尚未得到很好的确定。9p 杂合性缺失是胶质瘤的一种典型分子特征，但 9p 杂合性缺失是否与胶质瘤患者的生存较差有关仍不清楚。我们检索了 PubMed 和 Embase 数据库，检索时间为最早记录至 2015 年 5 月，以确定符合纳入标准的研究。根据研究间异质性，采用固定效应模型或随机效应模型计算合并风险比（HR）。共纳入 13 项符合条件的研究，包括 1465 例胶质瘤患者。研究间异质性较小（I²=15%），采用固定效应模型计算合并 HR。13 项研究的荟萃分析表明，9p 杂合性缺失与胶质瘤患者的预后较差显著相关（HR=1.39，95%CI 1.17-1.64，P=0.0002）。对 8 项报告调整后估计值的研究进行荟萃分析显示，9p 杂合性缺失与胶质瘤患者的预后较差独立相关（HR=1.40，95%CI 1.14-1.72，P=0.001）。根据胶质瘤类型的亚组分析显示，9p 杂合性缺失与胶质母细胞瘤患者的预后较差显著相关（HR=1.34，95%CI 1.01-1.78，P=0.04）。漏斗图未显示明显的发表偏倚风险。9p 杂合性缺失与胶质瘤患者的预后显著相关，是预测患者生存的有用生物标志物。
